vs
Amneal Pharmaceuticals, Inc.（AMRX）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
Rollins, Inc.的季度营收约是Amneal Pharmaceuticals, Inc.的1.3倍（$906.4M vs $722.5M），Rollins, Inc.净利率更高（11.9% vs 10.8%，领先1.1%），Rollins, Inc.同比增速更快（10.2% vs 3.9%），过去两年Amneal Pharmaceuticals, Inc.的营收复合增速更高（1.5% vs 0.8%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
AMRX vs ROL — 直观对比
营收规模更大
ROL
是对方的1.3倍
$722.5M
营收增速更快
ROL
高出6.3%
3.9%
净利率更高
ROL
高出1.1%
10.8%
两年增速更快
AMRX
近两年复合增速
0.8%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $722.5M | $906.4M |
| 净利润 | $78.0M | $107.8M |
| 毛利率 | 44.3% | — |
| 营业利润率 | — | 16.1% |
| 净利率 | 10.8% | 11.9% |
| 营收同比 | 3.9% | 10.2% |
| 净利润同比 | 217.0% | 2.5% |
| 每股收益（稀释后） | $0.19 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXROL
| Q1 26 | $722.5M | $906.4M | ||
| Q4 25 | $814.3M | $912.9M | ||
| Q3 25 | $784.5M | $1.0B | ||
| Q2 25 | $724.5M | $999.5M | ||
| Q1 25 | $695.4M | $822.5M | ||
| Q4 24 | $730.5M | $832.2M | ||
| Q3 24 | $702.5M | $916.3M | ||
| Q2 24 | $701.8M | $891.9M |
净利润AMRXROL
| Q1 26 | $78.0M | $107.8M | ||
| Q4 25 | $35.1M | $116.4M | ||
| Q3 25 | $2.4M | $163.5M | ||
| Q2 25 | $22.4M | $141.5M | ||
| Q1 25 | $12.2M | $105.2M | ||
| Q4 24 | $-31.1M | $105.7M | ||
| Q3 24 | $-156.0K | $136.9M | ||
| Q2 24 | $6.0M | $129.4M |
毛利率AMRXROL
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | 35.6% | — |
营业利润率AMRXROL
| Q1 26 | — | 16.1% | ||
| Q4 25 | 13.8% | 17.5% | ||
| Q3 25 | 9.0% | 21.9% | ||
| Q2 25 | 15.4% | 19.8% | ||
| Q1 25 | 14.4% | 17.3% | ||
| Q4 24 | 10.4% | 18.1% | ||
| Q3 24 | 12.6% | 20.9% | ||
| Q2 24 | 13.6% | 20.4% |
净利率AMRXROL
| Q1 26 | 10.8% | 11.9% | ||
| Q4 25 | 4.3% | 12.8% | ||
| Q3 25 | 0.3% | 15.9% | ||
| Q2 25 | 3.1% | 14.2% | ||
| Q1 25 | 1.8% | 12.8% | ||
| Q4 24 | -4.3% | 12.7% | ||
| Q3 24 | -0.0% | 14.9% | ||
| Q2 24 | 0.9% | 14.5% |
每股收益（稀释后）AMRXROL
| Q1 26 | $0.19 | $0.22 | ||
| Q4 25 | $0.10 | $0.24 | ||
| Q3 25 | $0.01 | $0.34 | ||
| Q2 25 | $0.07 | $0.29 | ||
| Q1 25 | $0.04 | $0.22 | ||
| Q4 24 | $-0.10 | $0.22 | ||
| Q3 24 | $0.00 | $0.28 | ||
| Q2 24 | $0.02 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $116.5M |
| 总债务越低越好 | — | $650.6M |
| 股东权益账面价值 | — | $1.4B |
| 总资产 | — | $3.2B |
| 负债/权益比越低杠杆越低 | — | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资AMRXROL
| Q1 26 | — | $116.5M | ||
| Q4 25 | $282.0M | $100.0M | ||
| Q3 25 | $201.2M | $127.4M | ||
| Q2 25 | $71.5M | $123.0M | ||
| Q1 25 | $59.2M | $201.2M | ||
| Q4 24 | $110.6M | $89.6M | ||
| Q3 24 | $74.0M | $95.3M | ||
| Q2 24 | $43.8M | $106.7M |
总债务AMRXROL
| Q1 26 | — | $650.6M | ||
| Q4 25 | $2.6B | $486.1M | ||
| Q3 25 | $2.6B | $485.7M | ||
| Q2 25 | $2.2B | $485.3M | ||
| Q1 25 | $2.2B | $485.5M | ||
| Q4 24 | $2.4B | $395.3M | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — |
股东权益AMRXROL
| Q1 26 | — | $1.4B | ||
| Q4 25 | $-70.8M | $1.4B | ||
| Q3 25 | $-109.5M | $1.5B | ||
| Q2 25 | $-112.1M | $1.4B | ||
| Q1 25 | $-131.7M | $1.4B | ||
| Q4 24 | $-109.3M | $1.3B | ||
| Q3 24 | $-93.4M | $1.3B | ||
| Q2 24 | $-57.5M | $1.2B |
总资产AMRXROL
| Q1 26 | — | $3.2B | ||
| Q4 25 | $3.7B | $3.1B | ||
| Q3 25 | $3.6B | $3.2B | ||
| Q2 25 | $3.4B | $3.2B | ||
| Q1 25 | $3.4B | $2.9B | ||
| Q4 24 | $3.5B | $2.8B | ||
| Q3 24 | $3.5B | $2.8B | ||
| Q2 24 | $3.5B | $2.8B |
负债/权益比AMRXROL
| Q1 26 | — | 0.47× | ||
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | — | 0.30× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $118.4M |
| 自由现金流经营现金流 - 资本支出 | — | $111.2M |
| 自由现金流率自由现金流/营收 | — | 12.3% |
| 资本支出强度资本支出/营收 | — | 0.8% |
| 现金转化率经营现金流/净利润 | — | 1.10× |
| 过去12个月自由现金流最近4个季度 | — | $621.1M |
8季度趋势，按日历期对齐
经营现金流AMRXROL
| Q1 26 | — | $118.4M | ||
| Q4 25 | $130.3M | $164.7M | ||
| Q3 25 | $118.5M | $191.3M | ||
| Q2 25 | $83.8M | $175.1M | ||
| Q1 25 | $7.4M | $146.9M | ||
| Q4 24 | $118.1M | $188.2M | ||
| Q3 24 | $141.8M | $146.9M | ||
| Q2 24 | $39.7M | $145.1M |
自由现金流AMRXROL
| Q1 26 | — | $111.2M | ||
| Q4 25 | $108.5M | $159.0M | ||
| Q3 25 | $106.2M | $182.8M | ||
| Q2 25 | $61.0M | $168.0M | ||
| Q1 25 | $-5.8M | $140.1M | ||
| Q4 24 | $102.9M | $184.0M | ||
| Q3 24 | $124.8M | $139.4M | ||
| Q2 24 | $29.0M | $136.4M |
自由现金流率AMRXROL
| Q1 26 | — | 12.3% | ||
| Q4 25 | 13.3% | 17.4% | ||
| Q3 25 | 13.5% | 17.8% | ||
| Q2 25 | 8.4% | 16.8% | ||
| Q1 25 | -0.8% | 17.0% | ||
| Q4 24 | 14.1% | 22.1% | ||
| Q3 24 | 17.8% | 15.2% | ||
| Q2 24 | 4.1% | 15.3% |
资本支出强度AMRXROL
| Q1 26 | — | 0.8% | ||
| Q4 25 | 2.7% | 0.6% | ||
| Q3 25 | 1.6% | 0.8% | ||
| Q2 25 | 3.2% | 0.7% | ||
| Q1 25 | 1.9% | 0.8% | ||
| Q4 24 | 2.1% | 0.5% | ||
| Q3 24 | 2.4% | 0.8% | ||
| Q2 24 | 1.5% | 1.0% |
现金转化率AMRXROL
| Q1 26 | — | 1.10× | ||
| Q4 25 | 3.72× | 1.41× | ||
| Q3 25 | 50.00× | 1.17× | ||
| Q2 25 | 3.74× | 1.24× | ||
| Q1 25 | 0.61× | 1.40× | ||
| Q4 24 | — | 1.78× | ||
| Q3 24 | — | 1.07× | ||
| Q2 24 | 6.62× | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
ROL
暂无分部数据
